ClinicalTrials.gg

Program

lonoctocog alfa

Also written as “rVIII-SingleChain” and “Recombinant single-chain factor VIII (rVIII-SingleChain)”.

Its studies are mostly in Hemophilia A, led by CSL.

Furthest: phase 3, since Nov 19, 20114 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL40 open or runningphase 3since Nov 19, 2011Nov 19, 2011none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2011First study: phase 3 study in Hemophilia AFirst studyNCT01486927 · 175 enrolled · United States, Australia, Austria and more
  2. Mar 19, 2014Phase 3 study in Hemophilia ANCT02093897 · 84 enrolled · United States, Australia, Austria and more
  3. Jun 23, 2014Phase 3 study in Hemophilia ANCT02172950 · 246 enrolled · United States, Australia, Austria and more
  4. Dec 12, 2024Phase 3 study in Hemophilia ANCT06738485 · 62 enrolled · China

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
antihemophilic factor, human recombinantruleTakedaphase 416
efanesoctocog alfaruleSanofiphase 412
omfiloctocog alfaruleSinocelltech Groupphase 46

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06738485Hemophilia A · China3CompletedSep 23, 202662
NCT02172950Hemophilia A · United States, Australia, Austria and more3CompletedJan 19, 2021246
NCT02093897Hemophilia A · United States, Australia, Austria and more3CompletedAug 201584
NCT01486927Hemophilia A · United States, Australia, Austria and more3CompletedDec 2014175

How it is read

Names in the registry

  • “rVIII-SingleChain”, 3 entries
  • “Recombinant single-chain factor VIII (rVIII-SingleChain)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.